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Objectives The purpose of this study was to assess the impact on cardiovascular and adverse events of attaining low-
density lipoprotein cholesterol (LDL-C) levels 50 mg/dl with rosuvastatin in apparently healthy adults in the
JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial.
Background The safety and magnitude of cardiovascular risk reduction conferred by treatment to LDL-C levels below current
recommended targets remain uncertain.
Methods A cohort of 17,802 apparently healthy men and women with high-sensitivity C-reactive protein 2 mg/l and
LDL-C 130 mg/dl were randomly allocated to rosuvastatin 20 mg daily or placebo, and followed up for all-
cause mortality, major cardiovascular events, and adverse events. In a post-hoc analysis, participants allocated
to rosuvastatin were categorized as to whether or not they had a follow-up LDL-C level 50 mg/dl.
Results During a median follow-up of 2 years (range up to 5 years), rates of the primary trial endpoint were 1.18, 0.86,
and 0.44 per 100 person-years in the placebo group (n  8,150) and rosuvastatin groups without LDL-C 50
mg/dl (n  4,000) or with LDL-C 50 mg/dl (n  4,154), respectively (fully-adjusted hazard ratio: 0.76; 95%
confidence interval: 0.57 to 1.00 for subjects with no LDL-C 50 mg/dl vs. placebo and 0.35, 95% confidence
interval: 0.25 to 0.49 for subjects attaining LDL-C 50 mg/dl; p for trend 0.0001). For all-cause mortality, cor-
responding event rates were 0.67, 0.65, and 0.39 (p for trend  0.004). Rates of myalgia, muscle weakness,
neuropsychiatric conditions, cancer, and diabetes mellitus were not significantly different among rosuvastatin-
allocated participants with and without LDL-C 50 mg/dl.
Conclusions Among adults with LDL-C 130 mg/dl and high-sensitivity C-reactive protein 2 mg/l, rosuvastatin-
allocated participants attaining LDL-C 50 mg/dl had a lower risk of cardiovascular events without a
systematic increase in reported adverse events. (J Am Coll Cardiol 2011;57:1666–75) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.09.082Current guidelines suggest reducing low-density lipoprotein
cholesterol (LDL-C) to 70 mg/dl in high-risk patients
(1), and clinical trials have found the lowest cardiovascular
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Although statin therapy is highly effective at lowering
LDL-C and reducing vascular risk (2,6,7), concern persists
that very low levels of cholesterol after aggressive use of
statins may be associated with adverse clinical effects (8).
For example, inadequate cholesterol levels have been pro-
posed to affect serotonin and steroid hormone production,
vitamin transport, and cell membrane function, with puta-
tive health consequences ranging from neuropsychiatric
conditions to cancer (9–13). Conversely, paleolithic ances-
tors consuming a hunter-gatherer diet appeared largely free
of degenerative cardiovascular disease (14,15), and persons
with genetic mutations that affect LDL-C levels, such as
PCSK9, have very low LDL-C levels during life, low
vascular risk, and no apparent adverse effects (16).
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risk reduction among adults attaining LDL-C 50 mg/dl, a
level below current recommended targets, in the JUPITER
(Justification for the Use of Statins in Prevention: an Interven-
tion Trial Evaluating Rosuvastatin) trial (17,18).
Methods
Study design and population. The JUPITER trial partic-
ipants were men age 50 years or older (n  11,001) and
women age 60 years or older (n  6,801) with LDL-C
130 mg/dl, high-sensitivity C-reactive protein (hsCRP)
2.0 mg/l, and no history of cardiovascular disease or
diabetes mellitus (17,18). Current users of post-menopausal
hormone therapy or immunosuppressive agents were ex-
cluded, as were those with chronic inflammatory conditions
such as severe arthritis, lupus, or inflammatory bowel
disease, or with cancer within the preceding 5 years. Local
institutional review boards approved the study, and all
participants provided written, informed consent.
Potentially eligible subjects underwent a 4-week placebo
run-in phase; those with compliance 80% were randomly
allocated to rosuvastatin 20mg daily or to placebo and followed
up for occurrence of the primary endpoint, a composite of
myocardial infarction (MI), stroke, arterial revascularization,
unstable angina, or confirmed death from cardiovascular
Baseline Characteristics by Treatment Group anTable 1 Baseline Characteristics by Treatm
Placebo
n 8,150
Age, yrs 66 (60–71)
Women 3,081 (38)
Ethnicity
White 5,854 (72)
Black 1,012 (12)
Hispanic 1,012 (12)
Asian 119 (2)
Other/unknown 153 (2)
Body mass index, kg/m2 28 (25–32)
Systolic BP, mm Hg 134 (124–145)
Diastolic BP, mm Hg 80 (75–87)
Current smoker 1,283 (16)
Family history of CHD 969 (12)
LDL-C, mg/dl 109 (94–119)
HDL-C, mg/dl 49 (40–60)
Triglycerides, mg/dl 118 (86–170)
Total cholesterol, mg/dl 185 (169–199)
Glucose, mg/dl 94 (88–102)
Hemoglobin A1C, % 5.7 (5.5–5.9)
eGFR, ml/min/1.73 m2 74 (65–84)
Impaired fasting glucose 2,581 (32)
hsCRP, mg/l 4.3 (2.8–7.1)
Data are presented as n, median (interquartile range), or n (%).
BP  blood pressure; CHD  coronary heart disease; eGFR  estimated gl
hsCRP  high-sensitivity C-reactive protein; LDL-C  low-density lipoprotein ccauses. An independent endpoint
committee adjudicated primary
endpoint events.
Clinic physicians reported ad-
verse events as verbatim terms,
which were coded toMedical Dic-
tionary for Regulatory Activities
preferred terms (19) by an auto-
mated system, over-read by trained
coders. We report treatment-
emergent adverse events, that is,
events that either began or wors-
ened after randomization. Ad-
verse events were not adjudi-
cated, except for hemorrhagic
stroke, which was a subcategory
of stroke, a component of the
primary endpoint.
The trial’s pre-specified mon-
itoring plan called for 2 interim efficacy analyses with
O’Brien-Fleming stopping boundaries determined by
means of the Lan-DeMets approach. The stopping bound-
ary was crossed at the first pre-specified efficacy evaluation
in September 2007; however, the independent data and
safety monitoring board conservatively sought “proof be-
yond a reasonable doubt” and voted to continue the trial at
ained LDL-Croup and Attained LDL-C
Rosuvastatin
No LDL-C
<50 mg/dl
LDL-C
<50 mg/dl
4,000 4,154
66 (60–71) 66 (61–72)
1,604 (40) 1,520 (37)
2,793 (70) 3,106 (75)
515 (13) 476 (12)
514 (13) 456 (11)
88 (2) 44 (1)
90 (2) 72 (2)
28 (25–32) 29 (26–32)
134 (124–145) 135 (124–147)
80 (75–87) 80 (75–88)
646 (16) 623 (15)
431 (11) 499 (12)
113 (101–122) 103 (87–115)
49 (41–60) 48 (40–59)
115 (82–164) 122 (88–175)
190 (175–203) 181 (163–196)
93 (87–101) 95 (88–102)
5.7 (5.4–5.9) 5.7 (5.4–5.9)
75 (65–87) 73 (64–83)
1,133 (28) 1,402 (34)
4.3 (2.8–7.1) 4.2 (2.8–7.0)
Abbreviations
and Acronyms
ALT  alanine
aminotransferase
CHD  coronary heart
disease
CI  confidence interval
eGFR  estimated
glomerular filtration rate
HDL-C  high-density
lipoprotein cholesterol
HR  hazard ratio
hsCRP  high-sensitivity
C-reactive protein
LDL-C  low-density
lipoprotein cholesterol
MI  myocardial infarctiond Attent Gomerular filtration rate; HDL-C  high-density lipoprotein
holesterol.cholesterol;
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confirmed primary endpoints had occurred (nominal hazard
ratio [HR]: 0.57, 95% confidence interval [CI]: 0.46 to
0.72), and the board voted unanimously to recommend
termination of the trial. The steering committee accepted
that recommendation, and only major cardiovascular events
occurring before March 30, 2008, are included in the
primary endpoint analysis. Reporting of adverse events and
all-cause mortality continued in a blinded manner until each
participant appeared for a close-out visit and discontinued
study medication.
Participants provided fasting blood samples for lipid
profiles at baseline, annually thereafter, and at the final visit.
Figure 1 Cardiovascular Events and All-Cause Mortality by Bas
Numbers of patients with baseline low-density lipoprotein cholesterol (LDL-C) in ea
primary endpoint, the primary endpoint or death, and the composite of the primary
Independent Predictors of AttainingLDL-C <50 mg/ l at Any VisitAmong Rosuvastatin- ll cated Patients
Table 2
Ind pe de t Predictors of Attaining
LDL-C <50 mg/dl at Any Visit
Among Rosuvastatin-Allocated Patients
Variable Odds Ratio 95% CI p Value
Age 1.023 1.017–1.030 0.0001
Men (women, referent) 1.190 1.069–1.324 0.002
Impaired fasting glucose 1.251 1.129–1.385 0.0001
Adherence to study medication 1.025 1.022–1.029 0.0001
Body mass index 1.027 1.018–1.036 0.0001
Baseline LDL-C 0.968 0.965–0.971 0.0001
Baseline HDL-C 0.996 0.993–1.000 0.023
Baseline hsCRP 0.990 0.985–0.996 0.001
Sex and impaired fasting glucose were categorical variables in the multivariable logistic regression
model; all others were continuous variables.
CI  confidence interval; other abbreviations as in Table 1.Alanine aminotransferase (ALT) was measured, and urinal-
ysis was performed at baseline, at 3 and 6 months after
randomization, semiannually thereafter, and at the final
visit. Creatine kinase was measured at baseline and final
visit, and at physician discretion for muscle symptoms. We
estimated glomerular filtration rate (eGFR) by the Modifi-
cation of Diet in Renal Disease study equation (20).
Statistical analyses. This post-hoc analysis includes all
randomized JUPITER participants with at least 1 post-
randomization lipid profile (n  16,304). Subjects were
categorized according to their allocated treatment group
and, within the rosuvastatin group, by attained LDL-C
level. Those with 1 or more post-randomization LDL-C
levels 50 mg/dl were categorized as having attained
LDL-C 50 mg/dl; the remaining rosuvastatin-allocated
subjects were categorized as not having attained LDL-C
50 mg/dl. Clinical event rates of placebo-allocated sub-
jects were compared with rosuvastatin-allocated participants
attaining LDL-C 50 mg/dl and, separately, to partici-
pants not attaining LDL-C 50 mg/dl. In addition, events
were compared between rosuvastatin-allocated participants
who did and did not attain LDL-C 50 mg/dl.
Within the rosuvastatin group, we identified independent
predictors of attaining LDL-C 50 mg/dl by multivariable
logistic regression. The HR and 95% CI were calculated
from Cox proportional hazard models; because a primary
interest for this analysis was in nonrandomized comparisons
of subjects with or without LDL-C 50 mg/dl, all HRs
LDL-C Level
egory, hazard ratios, and 95% confidence intervals for time to occurrence of the
int, venous thromboembolism (VTE), or death are shown by baseline LDL-C level.eline
ch cat
endpo
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index, systolic blood pressure, smoking status, impaired
fasting glucose status, and baseline levels of LDL-C, high-
density lipoprotein cholesterol [HDL-C], and hsCRP)
(17). Linear trends were analyzed. Change in eGFR was
compared between groups by analysis of covariance including
baseline eGFR as a covariate and fully adjusted for the
covariates listed in the preceding text. Analyses were performed
using SAS version 8.2 (SAS Institute, Cary, North Carolina).
Results
Baseline characteristics of the placebo group and rosuvasta-
tin group are summarized in Table 1, the latter according to
attained LDL-C concentration. Median follow-up was 2.0
years in the placebo group, and 1.9 and 2.0 years, respec-
tively, in rosuvastatin-allocated subjects without and with
LDL-C levels 50 mg/dl. Baseline and 1-year LDL-C
levels (median) were 109 and 110 mg/dl in the placebo
group, 113 and 70 mg/dl in rosuvastatin-allocated subjects
with no LDL-C 50 mg/dl, and 103 and 44 mg/dl in
rosuvastatin-allocated patients with LDL-C 50 mg/dl.
Figure 2 Time to Occurrence of Major Cardiovascular Events A
Kaplan-Meier curves for the primary study endpoint, time to first occurrence of car
ized unstable angina for subjects allocated to placebo (solid line), rosuvastatin wi
astatin with LDL-C 50 mg/dl (dotted line); p for trend 0.0001.Medication adherence, defined as taking at least 80% of
the prescribed study medication, was 88.3% in the placebo
group and 82.6% and 94.9% in rosuvastatin-allocated sub-
jects without and with LDL-C 50 mg/dl, respectively.
Among rosuvastatin-allocated JUPITER study participants,
independent predictors of attaining LDL-C 50 mg/dl
included slightly older age, greater medication adherence,
higher body mass index, impaired fasting glucose status, and
lower baseline levels of LDL-C, HDL-C, and hsCRP
(Table 2). Ethnicity was not an independent determinant of
attaining LDL-C 50 mg/dl.
We have previously reported that rosuvastatin reduced the
primary study endpoint, a composite of cardiovascular death,
MI, stroke, arterial revascularization, and unstable angina, by
44% (HR: 0.56, 95% CI: 0.46 to 0.69; p 0.0001) (18). This
treatment effect was consistent regardless of baseline LDL-C
level (Fig. 1). In contrast, the magnitude of clinical benefit was
directly related to attained LDL-C level (Fig. 2). Compared
with placebo, rosuvastatin-allocated patients with no LDL-C
50 mg/dl had a smaller risk reduction for the primary
endpoint (fully-adjusted HR: 0.76 vs. placebo, 95% CI: 0.57 to
1.00) compared with patients with LDL-C 50 mg/dl (HR:
ing to Treatment Group and Achieved LDL-C Concentrations
cular death, myocardial infarction, stroke, arterial revascularization, or hospital-
low-density lipoprotein cholesterol (LDL-C) 50 mg/dl (dashed line), and rosuv-ccord
diovas
th no
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relationship between attained LDL-C and cardiovascular risk
reduction was consistent among pre-specified subgroups of
patients categorized by baseline characteristics (Fig. 3).
We observed similar relationships between attained
LDL-C and clinical event reduction for the pre-specified
endpoint of MI, stroke, or cardiovascular death (fully-
adjusted HR: 0.78, 95% CI: 0.55 to 1.12 vs. HR: 0.26, 95%
CI: 0.16 to 0.43 for patients without and with LDL-C50
mg/dl, respectively; p for trend 0.0001), for all-cause
mortality (fully-adjusted HR: 1.15, 95% CI: 0.83 to 1.58 vs.
HR: 0.54, 95% CI: 0.37 to 0.78 for patients without and
with LDL-C50 mg/dl, respectively; p for trend 0.004),
Figure 3 Primary Endpoint in Pre-Specified Subgroups Within JU
Hazard ratios and 95% confidence intervals for the primary endpoint are shown fo
pared with placebo and for rosuvastatin-allocated patients with versus without LDL
0.05, except for family history (Hx) of premature coronary heart disease (CHD) in
action  0.003) and white versus nonwhite ethnicity for rosuvastatin-allocated pa
mass index.and for the post-hoc composite of the primary endpoint,venous thromboembolism, and death (fully-adjusted HR:
0.85, 95% CI: 0.68 to 1.04 vs. HR: 0.41, 95% CI: 0.32 to
0.53 for patients without and with LDL-C 50 mg/dl,
respectively; p for trend 0.0001) (Fig. 4).
We also directly compared clinical outcomes in analyses
limited to patients treated with rosuvastatin who did or did
not attain LDL-C 50 mg/dl during follow-up. As also
shown in Figure 4, compared with patients who did not
attain LDL-C 50 mg/dl, patients who did had a fully-
adjusted HR for the primary trial endpoint of 0.39 (95% CI:
0.26 to 0.59; p  0.0001). A similar relationship was
observed for the pre-specified endpoint of MI, stroke, and
cardiovascular death (fully-adjusted HR: 0.29, 95% CI: 0.16
R Trial, Stratified by Achieved LDL-C
nts without and with low-density lipoprotein cholesterol (LDL-C) 50 mg/dl com-
0 mg/dl. Among the 30 subgroups assessed, p values for interaction were all
osuvastatin-allocated group without LDL 50 mg/dl versus placebo (p for inter-
with versus without LDL-C 50 mg/dl (p for interaction  0.03). BMI  bodyPITE
r patie
-C 5
the r
tientsto 0.52; p  0.0001), for all-cause mortality (fully-adjusted
e
w
L
g
p
m
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net clinical benefit endpoint that included the primary
endpoint, venous thromboembolism, and total mortality
(fully-adjusted HR: 0.44, 95% CI: 0.33 to 0.60; p 
0.0001). These effects were generally consistent across
pre-specified subgroups (Fig. 3).
Rates of adverse events were similar in the placebo and
rosuvastatin groups except for a slightly higher rate of
muscle symptoms with rosuvastatin (Table 3). Rates of
myalgia, muscle weakness, and myopathy were not signifi-
cantly different among rosuvastatin-allocated patients with
and without LDL-C 50 mg/dl. Diabetes mellitus as an
adverse event was reported more frequently among
rosuvastatin-allocated patients attaining LDL-C 50
mg/dl than among rosuvastatin-allocated patients who did
not attain LDL-C 50 mg/dl, but this difference was not
significant (1.6 vs. 1.2 per 100 person-years, p  0.70).
Rates of psychiatric adverse events, fatigue, peripheral neu-
ropathy, cancer, hematuria, proteinuria, and renal failure did
not differ between the rosuvastatin and placebo groups.
Reports of hematuria were more frequent (p  0.03) in
rosuvastatin-allocated patients with LDL-C 50 mg/dl
when compared with placebo, whereas depression (p 
0.005) and colon cancer (p  0.04) were reported less
Figure 4 Fully-Adjusted Hazard Ratios for Incident Cardiovascu
All-Cause Mortality According to Treatment Group and
Event rates are per 100 person-years. Low-density lipoprotein cholesterol (LDL-C) n
indicates rosuvastatin group with at least 1 LDL-C level 50 mg/dl. The p for tren
group. CV  cardiovascular; HR  hazard ratio; MI  myocardial infarction; VTE frequently. tHemorrhagic stroke, an adjudicated component of the
primary efficacy endpoint, was identified in 8 subjects in the
placebo group and 5 in the rosuvastatin group (rates of 0.04
and 0.03 per 100 person-years, respectively). Within the
rosuvastatin group, hemorrhagic stroke was identified in 4
patients without and 1 patient with LDL-C 50 mg/dl.
ALT elevation to 3 times the upper limit of normal was
more frequent with rosuvastatin than with placebo (p 
0.01), as were 2 category increases (e.g., negative/trace to
) in urine dipstick for protein (p  0.01) and blood
(p  0.01) (Table 4). Within the rosuvastatin group, ALT
levation and dipstick proteinuria and hematuria occurred
ith similar frequency in participants without and with
DL-C 50 mg/dl. The eGFR fell in both the placebo
roup and the rosuvastatin group during the follow-up
eriod; there was no evidence that rosuvastatin or attain-
ent of LDL-C 50 mg/dl adversely affected eGFR.
iscussion
osuvastatin reduced major cardiovascular events by 44%
ompared with placebo for the entire JUPITER study
ohort, and by 65% among those attaining LDL-C 50
g/dl. Similarly, all-cause mortality was reduced by 20% for
ents and
ieved Concentrations of LDL-C
0 indicates rosuvastatin (RSV) group without LDL-C level 50 mg/dl; LDL-C 50
ates trend across placebo group, LDL-C not 50 group, and LDL-C 50 mg/dl
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and diabetes mellitus were somewhat more common among
participants attaining LDL-C 50 mg/dl, but these rates
were not significantly different from rates among patients
not attaining LDL-C 50 mg/dl. Rates of other adverse
events, including muscle weakness, myopathy, neuropsychi-
atric events, renal dysfunction, hemorrhagic stroke, and
cancer, were not higher among patients allocated to rosu-
vastatin than among participants allocated to placebo, re-
gardless of attained LDL-C level.
A major strength of this analysis is its large sample size;
the number of JUPITER study participants with LDL-C
Numbers and Rates (per 100 Person-Years) of Treatment-EmergentTable 3 Numbers and Rates (per 100 Person-Years) of Treatme
System Organ Class Preferred Term(s)
Placebo
(n  8,150)
n Rate n
Any adverse event 6,509 103.1 3,126
Musculoskeletal/connective tissue disorders 2,930 21.7 1,489
Myalgia 559 3.2 317
Muscular weakness 61 0.3 43
Rhabdomyolysis*/myopathy/myositis 9 0.05 3
Gastrointestinal disorders 2,106 14.0 980
Respiratory, thoracic, and mediastinal disorders 1,360 8.3 611
Nervous system disorders 1,431 8.8 628
Peripheral neuropathy† 40 0.2 18
Amyotrophic lateral sclerosis 2 0.01 0
Parkinson’s disease 13 0.1 5
Memory impairment‡ 33 0.2 21
General disorders/administration site conditions
Fatigue 297 1.7 133
Renal and urinary disorders 782 4.5 344
Hematuria 175 1.0 86
Proteinuria§ 111 0.6 55
Renal failure 70 0.4 32
Eye disorders
Cataract 195 1.1 72
Cancer 269 1.5 128
Prostate cancer¶ 53 0.3 12
Breast cancer# 23 0.1 12
Colon cancer** 28 0.2 10
Psychiatric disorders 619 3.6 307
Insomnia†† 205 1.1 104
Depression‡‡ 217 1.2 103
Anxiety§§ 158 0.9 66
Anger  4 0.02 0
Diabetes mellitus 209 1.2 105
Hepatobiliary disorders 177 1.0 71
*A 90-year-old man with laboratory-confirmed influenza lay on the floor overnight and developed r
terms neuropathy peripheral, polyneuropathy, demyelinating polyneuropathy, myelopathy, neuro
impairment, dementia, dementia Alzheimer’s type, and cognitive disorder. §Proteinuria includes p
terms renal failure, renal failure chronic, renal failure acute, renal impairment, azotemia, anuria, oli
cancer, prostate cancer recurrent, and prostate cancer metastatic. #Breast cancer includes prefe
cancer, colon cancer metastatic, colon cancer stage I, rectal cancer, rectosigmoid cancer, colon ca
‡‡Depression includes preferred terms depression, depressed mood, major depression, suicidal
includes preferred terms anxiety, nervousness, and generalized anxiety disorder.  Anger include
LDL-C  low-density lipoprotein cholesterol.50 mg/dl is greater than the entire active treatment groupof many controlled statin trials (2). Other strengths include
the diversity of the cohort, placebo-controlled design, inde-
pendent endpoint adjudication, and systematic adverse
event ascertainment. Adverse events were reported by clinic
physicians blinded to treatment assignment and on-
treatment LDL-C, but were not adjudicated. The major
limitation of this analysis is that classification into the 2
rosuvastatin groups is made on the basis of a nonrandom-
ized outcome (attainment of LDL-C 50 mg/dl); hence,
comparisons of these 2 groups to placebo or to each other
is subject to potential confounding bias from factors
correlated with LDL-C lowering. Because adherence to
erse Events by Treatment Group and Attained LDL-Cergent Adverse Events by Treatment Group and Attained LDL-C
Rosuvastatin
p Value vs.
No LDL-C
<50 mg/dl
DL-C <50 mg/dl
(n  4,000)
LDL-C <50 mg/dl
(n  4,154)
Rate
p Value vs.
Placebo n Rate
p Value vs.
Placebo
104.0 0.84 3,424 108.1 0.01 0.004
24.4 0.006 1,691 24.3 0.0001 0.23
4.0 0.03 326 3.5 0.08 0.49
0.5 0.03 30 0.3 0.75 0.11
0.04 0.61 7 0.07 0.56 0.56
14.0 0.62 1,142 14.4 0.26 0.32
8.0 0.43 766 8.9 0.10 0.08
8.3 0.10 720 8.3 0.27 0.60
0.2 0.79 20 0.2 0.53 0.72
0 0.10 1 0.01 — —
0.1 0.78 8 0.1 0.80 0.63
0.2 0.13 12 0.1 0.23 0.041
1.6 0.51 176 1.8 0.09 0.12
4.3 0.56 439 4.8 0.54 0.30
1.0 0.63 123 1.3 0.03 0.05
0.6 0.82 73 0.75 0.12 0.41
0.4 0.74 39 0.40 0.78 0.75
0.9 0.11 104 1.1 0.91 0.20
1.5 0.56 131 1.4 0.36 0.36
0.1 0.08 26 0.3 0.69 0.06
0.1 0.99 10 0.1 0.75 0.93
0.1 0.47 6 0.1 0.04 0.30
3.8 0.67 296 3.2 0.15 0.23
1.2 0.79 118 1.2 0.40 0.52
1.2 0.83 83 0.9 0.005 0.01
0.8 0.29 65 0.7 0.09 0.54
0 — 1 0.01 — —
1.2 0.025 151 1.6 0.06 0.70
0.8 0.35 108 1.1 0.43 0.27
yolysis after the study ended, but before his final visit. †Peripheral neuropathy includes preferred
hy, and peripheral sensory neuropathy. ‡Memory impairment includes preferred terms memory
d terms proteinuria, microalbuminuria, and nephrotic syndrome. Renal failure includes preferred
ephritis, glomerulonephritis, and nephropathy. ¶Prostate cancer includes preferred terms prostate
rms breast cancer and breast cancer metastatic. **Colon cancer includes preferred terms colon
ge III, and colorectal cancer. ††Insomnia includes preferred terms insomnia and initial insomnia.
n, completed suicide, suicide attempt, depression suicidal, and depressive symptom. §§Anxiety
red terms anger, aggression, and intermittent explosive disorder.Advnt-Em
No L
habdom
myopat
referre
guria, n
rred te
ncer sta
ideatiostudy medication would directly affect LDL-C categori-
1673JACC Vol. 57, No. 16, 2011 Hsia et al.
April 19, 2011:1666–75 Efficacy and Safety of LDL-C <50 mg/dlzation, the impact of adherence bias is difficult to assess.
However, some reassurance is gained in that the effects
were not meaningfully affected by adjustment for several
factors potentially correlated with LDL-C lowering. An
additional limitation is the early trial stoppage for benefit,
which truncated rosuvastatin exposure at a median of 2
years, although approximately 1,000 participants were
treated for up to 5 years. The JUPITER cohort included
only middle-aged and older adults with average or low
LDL-C and hsCRP 2 mg/dl, which may limit the
extent to which results are applicable to the broader
population.
Baseline characteristics differ slightly from prior JUPITER trial
reports (17,18), as this analysis excluded 1,498 participants
ALT or CK Elevation, Proteinuria, or Hematuria at Any Follow-Up ViTable 4 ALT or CK Elevation, Proteinuria, or Hematuria at Any
Placebo
(n  8,150)
N
n Rate n
ALT 3  ULN 84 0.5 56
CK 10  ULN 1 0.005 1
2 proteinuria 387 2.2 210
2 hematuria 531 3.0 295
eGFR change, ml/min/1.73 m2, mean (SD) 9.0 (13.5) 9.1
Alanine aminotransferase (ALT) was measured and urine protein and blood assessed by dipstick a
kinase (CK) was measured at baseline and final visits, and at clinic physician discretion for muscle
hsCRP, smoking status, systolic blood pressure, impaired fasting glucose status, body mass index,
to final visit] are adjusted for baseline eGFR.
NC  not calculated; ULN  upper limit of normal; other abbreviations as in Table 1.
Figure 5 Relation of Major Cardiovascular Event Rate to LDL-C
Placebo groups are indicated by open symbols, and statin groups by solid symbol
myocardial infarction (MI)/coronary heart disease (CHD) death; AFCAPS/TexCAPs (
baskets), fatal and nonfatal MI, angina, cardiac and sudden death, revascularizat
tion, unstable angina. Rosuvastatin (RSV)-treated participants without low-density
mg/dl (median 44 mg/dl) are plotted separately. (Data are from references 7, 19,
Study; ASCOT-LLA  Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering A
Evaluating Rosuvastatin; MEGA  Management of Elevated Cholesterol in the Primwith no post-randomization lipoprotein measurement.
Numbers of adverse events also differ due to the Medical
Dictionary for Regulatory Activities preferred terms speci-
fied for each adverse event and the exclusion of non–
treatment-emergent adverse events. However, analyses per-
formed using alternative adverse event definitions revealed
virtually identical outcomes.
Both favorable and unfavorable consequences have been
attributed to attainment of very low LDL-C (5,6,8,9). The
JUPITER study adds to existing trial data, reinforcing the
graded relationship between on-treatment LDL-C and
cardiovascular event reduction, and expanding the range
over which LDL-C lowering confers cardiovascular risk
reduction (Fig. 5) (7,21–23). Consistent with prior reports
Treatment Assignment and Attained LDL-Cw-Up Visit by Treat ent Assignment and Attained LDL-C
Rosuvastatin
p Value vs.
No LDL-C
<50 mg/dl
C <50 mg/dl
 4,000)
LDL-C <50 mg/dl
(n  4,154)
te
p Value vs.
Placebo n Rate
p Value vs.
Placebo
0.06 66 0.7 0.007 0.78
1 0.45 1 0.01 0.84 1.00
0.01 251 2.6 0.13 0.29
0.008 346 3.7 0.003 0.56
0.004 7.9 (13.1) 0.04 0.50
e, at 3 and 6 months after randomization, semiannually thereafter, and at the final visit. Creatine
ms. Rates are per 100 person-years. The p values are adjusted for age, sex, baseline LDL-C, HDL-C,
ily history. In addition, p values for change in estimated glomerular filtration rate (eGFR) [baseline
Year in Primary Prevention Trials
ical events for West of Scotland (blue circles) and ASCOT-LLA (green squares),
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tein cholesterol (LDL-C) 50 mg/dl (median 69 mg/dl) and with LDL-C 50
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Efficacy and Safety of LDL-C <50 mg/dl April 19, 2011:1666–75(2,5), LDL-C level at 1 year predicts subsequent cardiovas-
cular events in a multivariable adjusted model (p  0.002).
Lower targets for LDL-C remain controversial, will need to
be evaluated in prospective settings, and may not be achiev-
able among patients with very elevated LDL-C. Nonethe-
less, the JUPITER trial data provide reassurance regarding
the safety of treating with rosuvastatin at very low levels of
LDL-C.
Safety findings among patients attaining LDL-C 50
mg/dl were consistent with the established safety profile of
rosuvastatin (24). Elevation of ALT and dipstick protein-
uria and hematuria were more frequent with rosuvastatin
than with placebo, but within the rosuvastatin group, were
not more frequent among subjects attaining LDL-C 50
mg/dl. Proteinuria with statins is attributable to 3-hydroxy-
3-methylglutaryl-coenzyme A (HMG-CoA) reductase in-
hibition in proximal renal tubular cells, leading to reduced
protein reabsorption (25). Thus, concordance between pro-
teinuria and extent of LDL-C reduction with rosuvastatin
might have been expected, but was not observed. The
higher frequency of diabetes mellitus reported as an adverse
event is consistent with the 0.08% greater increase in
glycosylated hemoglobin observed with rosuvastatin in the
JUPITER trial (18). The mechanisms underlying the higher
rates of observed hematuria and reported diabetes mellitus
are not known.
Several other adverse consequences of either low choles-
terol or statin therapy have been proposed. Hemorrhagic
stroke has been reported in association with low cholesterol
(26–27); in the JUPITER trial, although the number of
hemorrhagic strokes was small, we found no increase in
hemorrhagic stroke with rosuvastatin, even among patients
with LDL-C 50 mg/dl. Cataract formation has been
linked to statins in canine studies (28), but no such
relationship has been confirmed in humans (29–31). We
found no increase in cataracts with rosuvastatin or with
attainment of LDL-C 50 mg/dl. Peripheral neuropathy
has been attributed to statin-mediated axonal degeneration
(10,11,32), but was no more frequent with rosuvastatin or
with attainment of LDL-C 50 mg/dl in the JUPITER
trial. Depression, anxiety, aggression, fatigue, cognitive
impairment, and insomnia have been ascribed to statins
through a variety of proposed mechanisms, including local-
ized low cholesterol levels in the brain, transient hypoper-
fusion, impairment of blood-brain barrier function, and
mitochondria-mediated effects (9,13,33). In the JUPITER
study, rates of psychiatric adverse events were similar in the
placebo and rosuvastatin groups, and in subjects with and
without LDL-C 50 mg/dl.
Cancer was more frequent with statin treatment in several
early placebo-controlled trials, although numbers of cases
were small (34,35). This issue has persisted despite meta-
analyses demonstrating no increase in cancer risk (36–38).
In the JUPITER study, rates of cancer were no different
with rosuvastatin than with placebo, and no higher among
subjects attaining LDL-C50 mg/dl. Cancer was a leadingcause of death in the JUPITER study, and fewer cancer
deaths were seen with rosuvastatin than with placebo (p 
.02) (18).
The cardiovascular prevention community has searched
or a threshold or a percent reduction below which further
DL-C lowering no longer reduces cardiovascular events
2). Our analysis suggests that this threshold, if it exists, may
e50 mg/dl (Fig. 5) or50% LDL-C reduction. In prior
nalyses from this cohort, we have similarly found greater
linical benefits among subjects who attain hsCRP levels
2 mg/l, an effect largely unrelated to LDL-C reduction
17). Among adults without prevalent cardiovascular disease
r diabetes, rosuvastatin was well tolerated during the term
f exposure in the JUPITER trial, and participants attaining
DL-C 50 mg/dl with rosuvastatin experienced fewer
ardiovascular events and lower all-cause mortality.
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